An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor HM61713 binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors, which also inhibit the EGFR wild type form. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
